摘要
肺动脉高压是以肺血管阻力进行性增加为临床特征的一组威胁生命的疾病，近10年来，肺动脉高压的研究取得了显著的进展，涉及2003年威尼斯会议修改的肺动脉高压的命名和分类、遗传基因的发现、应用分子生物学技术探讨其发病学以及内科和外科治疗效果的改善。前列环素及其类似物和内皮素受体拮抗剂的临床研究，使肺动脉高压在治疗的安全性和有效性方面均取得了长足的进步。
Pulmonary arterial hypertension（PAH） is a group of life-threatening diseases characterized clinically by progressive increase in pulmonary vascular resistance. The quite remarkable advances in the research of PAH have been gained over the past 10 years, ranging from the revised nomenclature and classification of PAH （as proposed at the Venice conference in 2003） ,the identification of a gene respon＇sible for inherited forms of the disease, the application of molecular biological techniques to explore its pathogenesis, to the improvenment of medical therapies and surgical interventions. Clinical studies in prostacyclins,prostacyclin analogus and endothelin receptor antagonists have greatly improved the safety and efficacy in the treatment of PAH.
出处
《国际呼吸杂志》
2007年第15期1188-1192,共5页
International Journal of Respiration
关键词
肺动脉高压
分类
诊治进展
Pulmonary arterial hypertension
Classification
Advances of diagnosis and treatment
